Potential Complications Associated with the Use of Biologic Agents for Psoriasis

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 207-213

  Zeichner, Joshua A ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; PLACEBO; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLAXIS; ANEMIA; ANKYLOSING SPONDYLITIS; BLOOD PRESSURE FLUCTUATION; CHILL; CHOLESTASIS; CLINICAL TRIAL; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DIZZINESS; DOSE RESPONSE; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; HEADACHE; HEPATITIS; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; JAUNDICE; LEUKOPENIA; LISTERIOSIS; LIVER FAILURE; LIVER TOXICITY; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; LYMPHOMA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHARYNGITIS; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS;

EID: 34047262893     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.01.010     Document Type: Review

References (57)

1. Hoekstra M., van Ede A.E., Haagsma C.J., et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62 5 (2003) 423-426
2. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 28 3 (1993) 466-469
3. Lowe N.J., Wieder J.M., Rosenbach A., et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 35 5 Pt 1 (1996) 710-719
4. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 6719 (1999) 530-534
5. Gupta A.K., Goldfarb M.T., Ellis C.N., et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20 6 (1989) 1088-1093
6. Gronhoj Larsen F., Steinkjer B., Jakobsen P., et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 143 6 (2000) 1164-1169
7. Weinberg J.M., Saini R., and Tutrone W.D. Biological therapy for psoriasis-the first wave: infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol 1 3 (2002) 303-310
8. Stern D.K., Tripp J.M., Ho V.C., et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 23 2 (2005) 259-300
9. Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol 49 (2003) S112-S117
10. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 357 (2001) 1842-1847
11. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356 (2000) 385-390
12. Goffe B., and Cather J.C. Etanercept: an overview. J Am Acad Dermatol 49 2 Suppl (2003) S105-S111 Review
13. Weinblatt M.E., Kremer J.M., and Bankhurst A.D. Trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
14. Etanercept [package insert] (2004), Immunex Corp, Thousand Oaks (CA)
15. Gottlieb A.B., Matheson R., Lowe N.J., et al. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 119 (2002) 234
16. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48 2 (2003) 319-324
17. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46 10 (2002) 2565-2570
18. Wallis R.S., Broder M., Wong J., et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl 3 (2005) S194-S198
19. Kaplan G., and Freedman V.H. The role of cytokines in the immune response to tuberculosis. Res Immunol 147 (1996) 565-572
20. Saunders B.M., and Cooper A.M. Restraining mycobacteria: the role of granulomas in mycobacterial infections. Immunol Cell Biol 78 (2000) 334-341
21. Mohan V.P., Scanga C.A., Yu K., et al. Effects of tumor necrosis factor alpaha on host immune response in the chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69 (2001) 1847-1855
22. Hamilton C.D. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 48 8 (2003) 2085-2091
23. CDC. Guide for primary health care providers: targeted tuberculin testing and treatment of latent tuberculosis infection 2005. Available at: http://www.cdc.gov/nchstp/tb/pubs//LTBI/default.htm. Accessed July 5, 2006.
24. Calabrese L. The yin and yang of tumor necrosis factor inhibitors. Cleve Clin J Med 73 3 (2006) 251-256
25. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44 (2005) 714-720
26. Kinlen L. Immunosuppressive therapy and acquired immunological disorders. Cancer Res 52 19 Suppl (1992) 5474s-5476s
27. Thomas E., Brewster D.H., Black R.J., et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88 3 (2000) 497-502
28. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 4 (2001) 854-862
29. Hochberg M.C., Lebwohl M., Plevy S.E., et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34 6 (2005) 819-836
30. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 12 (2002) 3151-3158
31. Robinson W.H., Genovese M.C., and Moreland L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 44 9 (2001) 1977-1983
32. Sicotte N.L., and Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57 10 (2001) 1885-1888
33. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 12 (2001) 2862-2869
34. Anker S.D., and Coats A.J. How to recover from Renaissance? The significance of the results of Recover, Renaissance, Renewal and Attach. Int J Cardiol 86 2-3 (2002) 123-130
35. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
36. Wolfe F., and Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116 (2004) 305-311
37. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (enbrel) in patients with advanced heart failure. Circulation 103 (2001) 1044-1047
38. Infliximab [package insert] (2005), Centocor, Inc, Malvern (PA)
39. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized trials. JAMA 295 19 (2006) 2275-2285
40. Bresnihan B., and Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 29 (2003) 185-202
41. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
42. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
43. Adalimumab [package insert] (2005), Abbott Laboratories, Chicago (IL)
44. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 (2003) 2563-2571
45. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 1 (2002) 1-23
46. Krueger J., Gottlieb A., Miller B., et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 115 (2000) 333
47. Cather J.C., Cather J.C., and Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 3 2 (2003) 361-370
48. Weinberg J.M. An overview of Infliximab, Etanercept, Efalizumab, and Alefacept as biologic therapy for Psoriasis. Clin Ther 25 (2003) 1-19
49. Efalizumab [package insert] (2005), Genentech, Inc, San Francisco (CA)
50. Leonardi C.L. Efalizumab in the treatment of psoriasis. Dermatol Ther 17 5 (2004) 393-400
51. Gaylor M.L., and Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 3 1 (2004) 77-79
52. Pietrzak A., Chodorowska G., Bartkowiak-Emeryk M., et al. Possibilities of using alefacept in the treatment of psoriasis. Ann Univ Mariae Curie Sklodowska 58 (2003) 311-313
53. Nickoloff B.J. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc 5 (2000) 67-73
54. Gade J.N. Clinical update on alefacept: consideration for use in patients with psoriasis. J Manag Care Pharm 10 3 Suppl B (2004) S33-S37
55. Gordon K.B., and Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2 6 (2003) 624-628
56. Alefacept [package insert] (2005), Biogen IDEC Inc, Cambridge (MA)
57. Lebwohl M., Enno C., and Langley R. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727